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1. INTRODUCTION 
Ilaprazole (ILA), chemically is known as 2-[(RS)-[(4-
methoxy-3-methylpyridin-2-yl)methyl]sulfinyl]-5-(1H-
pyrrol-1-yl)-1H-benzimidazole, (trade name Noltec) is 
a proton pump inhibitor (PPI) used in the treatment 
of dyspepsia, peptic ulcer 
disease (PUD), gastroesophageal reflux 
disease (GORD/GERD) and duodenal ulcer. 
Domperidone (DOM), chemically is known as 5-chloro-
1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-
yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-
benzodiazol-2-one, a specific blocker of dopamine 
receptors. It speeds gastrointestinal peristalsis, causes 
prolactin release, and is used as antiemetic and tool in the 
study of dopaminergic mechanisms. This combination of 
drugs will be used to treat peptic ulcers.1-2 
The literature is enriched with several methods for 
determination of ILA and DOM in pharmaceutical 
dosage forms either as a single drug or in combination 
with some other drugs. The most extensively used 
technique for estimation of ILA are by UV3 HPLC4, 
UPLC5 and LC-MS/MS6 methods and most extensively 
used technique for estimation of DOM are by UV 7-9 and 
RP-HPLC10-17. The aim of study is Development and 
Validation of Analytical HPLC method for Simultaneous 
Estimation of Ilaprazole and Domperidone in their 
combined Dosage form. 
The present study was designed to develop a simple, 
precise, and rapid analytical RP-HPLC procedure, which 
can be used for the analysis of assay method for 
simultaneous estimation of Ilaprazole and Domperidone 
as there was only individual methods reported for both 
drugs. The combination of these two drugs is not official 
in any pharmacopoeia; hence no official method is 
available for the simultaneous estimation of these two 
drugs in their combined dosage forms. Literature survey 
of Ilaprazole and Domperidone revealed several methods 
for detecting these drugs individually but there is no 
method for their simultaneous estimation using RP-
HPLC. 
                                                       
 
FIGURE 1: Chemical structure of Ilaprazole 
 
FIGURE 2: Chemical structure of Domperidone 
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ABSTRACT 
Ilaprazole is a proton pump inhibitor and Domperidone is a specific blocker of dopamine receptors. This combination of drugs 
will be used to treat peptic ulcers. In RP-HPLC method, a mobile phase of Phosphate Buffer (pH 3): Methanol (40:60 v/v) was 
used to resolve Ilaprazole and Domperidone from a mixture. Phenomex C18 column was used and flow rate was selected as 1 
ml/min. Detection was carried out at 229 nm which is Isobestic point of Ilaprazole and Domperidone. The linearity range 
obtained for the RP-HPLC method were 5 – 15 μg/ml and 15 - 45 μg/ml with corresponding correlation coefficient of 0.999 
and 0.999 for Ilaprazole and Domperidone respectively. The method was found to be rapid, accurate and precise. This method 
was validated according to ICH guidelines. 
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2. MATERIAL AND METHODS 
2.1 Apparatus and Instrument 
The analysis was carried out on a HPLC system 
(Shimadzu LC-20- AT) equipped with UV detector. 
Other apparatus and instruments used were a micro 
analytical balance (Shimadzu), Ultrasonic Cleaner (EIE 
Instruments Pvt. Ltd. Ahmedabad), Nylon Membrane 
Filters (0.22mcm, 47 mm D). All instruments and glass 
wares were calibrated. 
2.2 Reagents and Materials 
Ilaprazole and Domperidone were obtained as gratis 
sample from Accurate Pharmaceuticals, Godhra. 
Methanol HPLC Grade, Water HPLC Grade, Phosphate 
Buffer, O-Phosphoric Acid was used which were 
obtained from Samir Tech-Chem Pvt. Ltd. A stock-
standard solution of ILA and DOM was prepared by 
dissolving accurately weighed amount of pure drug in 
mobie phase. 
 2.3 Mobile Phase: Phosphate Buffer (pH 3): 
Methanol(40:60 v/v). The mobile phase was filtered 
through Millipore filter paper type HV (0.45 µm) and 
degassed by sonication. 
2.4 Chromatographic conditions 
Chromatographic analysis was carried out on an inertsil 
C-18 column, (5 µm, 250mm x 4.6mm i.d) LC-20 AT. 
The mobile phase consisted of Phosphate Buffer (pH 3): 
Methanol (40:60 v/v). The mobile phase was filtered 
through Millipore filter paper type HV (0.45 µm) and 
degassed by sonication, was pumped at 1.0 ml/min flow 
rate. The column was thermostated at room temperature. 
Under these conditions the runtime was 10 min. 
2.4.1 Preparation of standard stock solution of 
Ilaprazole (100 μg/ml) and Domperidone (300μg/ml) 
A 10 mg of standard Ilaprazole and 30 mg of standard 
Domperidone was weighed and transferred to a 100 ml 
volumetric flask each and dissolved in 25 ml mobile 
phase. The flask was shaken and volume was made up to 
the mark with mobile phase to give a solution containing 
100 μg/ml Ilaprazole and 300 μg/ml Domperidone. 
2.4.2 Preparation of combined working standard 
solution containing Ilaprazole and Domperidonein 
ratio of 1:3  
Accurately weighed 10 mg Ilaprazole and 30 mg of 
Domperidone were transferred to 100 ml volumetric 
flask, dissolved in sufficient amount of mobile phase and 
diluted up to mark with mobile phase to get 
concentration of 100 μg/ml  Ilaprazole and 300 μg/ml 
Domperidone. This solution was diluted further to get the 
concentrations in range of 5, 7.5, 10, 12.5, 15 μg/ml of 
Ilaprazole and 15, 22.5, 30, 37.5, 45 μg/ml of 
Domperidone. 
2.5 Method Validation 
2.5.1 Precision 
Repeatability: Precision of the method was studied by 
making repeated injections of the mixture of drugs on the 
same day for intraday precision. The % RSD after six 
determinations was determined at 10 µg/ml for ILA and 
30 µg/ml for DOM. 
Intraday and Inter-day Precision: Intraday and Inter-
day precision for method were measured in term of 
%RSD. The experiment was repeated three times in a 
day for intraday and on three different days of same for 
inter-day precision by taking lower, middle and higher 
concentration of ILA(5, 10, 15 µg/ml) and DOM(15, 30, 
45 µg/ml). 
2.5.2 Linearity: The linearity of measurement was 
evaluated by analyzing standard solutions of ILA and 
DOM in the range of 5–15 µg/ml and 15-45 µg/ml for 
both drugs respectively and calibration plot was 
constructed. 
2.5.3 Limit of Detection (LOD) and Limit of 
Quantitation (LOQ): LOD and LOQ of ILA and DOM 
were determined by calibration curve method. Solutions 
of Ilaprazole and Domperidone were prepared in the 
range of 5–15 µg/ml and 15-45 µg/ml for both drugs 
respectively and injected in triplicate. 
2.5.4 Accuracy: Accuracy of the method was calculated 
by recovery studies at three levels by standard addition 
method i.e. spiking 80%, 100%, 120% of ILA and DOM 
to the standard solutions containing 5 µg/ml of ILA and 
15 µg/ml of DOM. 
2.5.5 Robustness: Influence of small changes in 
chromatographic conditions such as change in flow rate, 
that is, ± 0.2 ml/min, mobile phase composition ±2 ml 
and pH ± 0.2 was studied to determine the robustness of 
the method for the development of RP-HPLC method for 
the simultaneous estimation of ILA and DOM and their 
%RSD was determined. 
2.5.6 System Suitability: The stock solution containing 
10 µg/ml of ILA and 30 µg/ml of DOM was injected and 
repeated five times and the chromatograms were 
recorded. The resolution, number of theoretical plates, 
and peak asymmetry were calculated to determine 
whether the result complies with the recommended limit.
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3. RESULTS AND DISCUSSION 
 
FIGURE 3: Chromatogram of ILA and DOM respectively 
3.1 Optimization of Chromatographic conditions 
To optimize the chromatographic conditions for 
separation of ILA and DOM, mobile phase composition, 
the effect of temperature and wavelength of detection 
investigated. 
During the method development work, enable C18 
column (25 cm× 4.6 mm i.d.) with particle size of 5 µm 
was used and gave the suitable resolution. The mobile 
phase composition was prepared with appropriate 
proportion of phosphate buffer (pH 3) : Methanol (40:60 
v/v).  
It was shown that the most efficient resolution and peak 
symmetry for Ilaprazole and Domperidone with a mobile 
phase composed of phosphate buffer (pH 3) : Methanol 
(40:60 v/v) and a flow rate of 1 ml/min. The retention 
time for Ilaprazole and Domperidone were found to be 
4.21 and 6.4 min respectively.  
The wavelength selected was the Isobestic point from the 
overlay of Ilaprazole and Domperidone. Both the drugs 
showed typical peak nature and peaks were symmetrical 
at 229 nm which is the Isobestic point. Hence the 
wavelength has been selected as the detection 
wavelength. 
3.2 Validation 
3.2.1 Linearity and Range 
The linearity of measurement was evaluated by 
analyzing standard solutions of ILA and DOM in the 
range of 5–15 µg/ml and 15-45 µg/ml respectively for 
both drugs and calibration plot was constructed. 
 
TABLE 1: Statistical parameters for Ilaprazole and Domperidone 
Statistical Parameter Ilaprazole Domperidone 
Average peak area* ± SD  560.67 ± 1.62 718.99 ± 1.66 
827.88 ± 1.53 1061.78 ± 1.73 
1131.98 ± 1.34 1451.96 ± 1.55 
1393.80 ± 1.50 1787.99 ± 1.49 
1695.92 ± 1.69 2175.68 ± 1.64 
Concentration Range (µg/ml) 5-15 15-45 
Straight line equation y = 113.46x - 12.517 y = 48.528x - 16.557 
Correlation coefficient (R
2
) 0.999 0.999 
LOD (μg/ml) 0.347 1.04 
LOQ (μg/ml) 1.05 3.16 
*n=5 
 
FIGURE 4: Calibration curve of Ilaprazole 
 
FIGURE 5: Calibration curve of Domperidone
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3.2.2 Precision 
Precision of the method was studied by making repeated 
injections of the mixture of drugs. The Relative Standard 
Deviation (%RSD) after six determinations was 0.7% at 
10 μg/ml for ILA and 0.81% at 30 μg/ml for DOM (see 
Table 2).  
 
TABLE 2: Precision data for ILA and DOM 
Precision Concentration found* (μg/ml) %RSD 
ILA DOM ILA DOM 
Repeatability 9.97 29.93 0.69 0.54 
Intraday Precision 5 15 0.88 1.19 
10 30.01 1.07 1.15 
14.99 44.99 0.61 0.86 
Interday Precision 5 15 0.63 0.72 
10 30.01 0.56 0.62 
14.99 44.99 0.46 0.56 
*n=6 
3.2.3 LOD and LOQ 
LOD and LOQ of ILA and DOM were determined by 
calibration curve method. Solutions of ILA and DOM 
were prepared in the range of 5–15 μg/ml and 15-45 
μg/ml respectively and injected in triplicate (see Table 
1). 
3.2.4 Accuracy 
Accuracy of the method was calculated by recovery 
studies at three levels by standard addition method. The 
mean percentage recoveries obtained for ILA and DOM 
were 99.61% and 99.64%, respectively (see Table 3).  
 
TABLE 3: Recovery data for ILA and DOM 
Lupila-D
®
 
Capsule 
Conc. in 
capsule 
(μg/ml) 
Conc. added 
(μg/ml) 
Total conc. 
found (μg/ml) 
Amount 
recovered 
(μg/ml) 
Mean 
Recovery* 
± SD 
(%) 
Ilaprazole 5 4 8.94 3.94 99.52 ± 0.65 
5 5 9.95 4.95 99.66 ± 0.65 
5 6 11 6 99.66 ± 0.48 
Domperidone 15 12 26.85 11.85 99.77 ± 0.83 
15 15 29.95 14.95 99.60 ± 0.43 
15 18 32.94 17.94 99.56 ± 0.27 
*n=3 
3.2.5 Robustness 
The method for the development of RP-HPLC method 
for the simultaneous estimation of ILA and DOM was 
found to be robust as the % RSD was found to be less 
than 2 (see Table 4) 
 
TABLE 4: Robustness data for ILA and DOM 
Parameters 
 
Variation % RSD 
ILA DOM 
 
 
Flow rate 
1.2 1.31 1.06 
(1 ml/min) 0.69 0.54 
0.8 0.75 0.97 
 
 
Mobile phase 
(42:58) 1.16 1.08 
Phosphate buffer pH 3 : Methanol (40:60) 0.69 0.54 
(38:62) 1.08 0.77 
 
 
pH (3) 
(3.2) 1.10 1.33 
pH (3) 0.69 0.54 
(2.8) 1.19 1.27 
 
3.2.6 System Suitability 
The resolution, number of theoretical plates, and peak 
asymmetry were calculated for the standard solutions. 
The stock solution containing 10 μg/ml of ILA and 30 
μg/ml of DOM was injected and repeated five times and 
the chromatograms were recorded. The resolution, 
number of theoretical plates, and peak asymmetry were 
calculated to determine whether the result complies with 
the recommended limit (see Table 5) 
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. TABLE 5: System Suitability Parameters 
 
Parameters 
Drugs 
Ilaprazole Domperidone 
Retention Time (min) 4.21 6.4 
Resolution (Rs) 9.636 
Tailing Factor (t) 0.91 1.38 
No. of theoretical plates 7488 9845 
 
TABLE 6: Summary of Validation Parameter: 
Sr. No. Parameters Results 
Ilaprazole Domperidone 
1. Linearity Range (n=5) (μg/ml) 5-15 15-45 
2. Regression equation y = 113.46x - 12.517 y = 48.528x - 16.557 
3. 
Correlation coefficient (R
2
) 
0.999 0.999 
4. Limit of detection (n=5) (μg/ml) 0.347 1.04 
5. Limit of quantification (n=5) (μg/ml) 1.05 3.16 
6. Precision   
Repeatability (%RSD) (n=6) 0.69 % 0.54 % 
Intraday (%RSD)(n=3) 0.86 % 1.07 % 
Interday (%RSD)(n=3) 0.55 % 0.68 % 
7. Robustness (%RSD) (n=3) 1.104 % 1.085 % 
8. Accuracy ( Mean ± SD)  
(%, n=3) 
99.61 ± 0.59 99.64 ± 0.51 
 
3.3 Procedure for the analysis of Capsule: 
Sample: Ilaprazole and Domperidone 
Brand name: LUPILA-D (Ilaprazole 10 mg, 
Domperidone30 mg) 
Manufacturer: Lupin Pharma, Mumbai, Maharashtra, 
India. 
3.3.1 Preperation of sample solution: 
LUPILA-D capsule containing 10 mg of ILA and 30 mg 
of DOM is available in local market which is marketed 
by Lupin Pharma(Mumbai). For estimation of Ilaprazole 
and Domperidone mixture was prepared. Mixture 
equivalent to 10 mg of Ilaprazole and 30 mg of 
Domperidone was accurately weighed and transferred to 
volumetric flask of 1000ml capacity. 25 ml of mobile 
phase was transferred to volumetric flask and Sonicate 
for 15 mins. The flask was shaken and volume was made 
up to the mark with mobile phase. The above solution 
was filtered through Whatman filter paper (0.75μ). From 
this solution 10 ml was transferred to volumetric flask of 
100 ml capacity. Volume was made up to the mark using 
mobile phase to give a solution containing 100 μg/ml 
Ilaprazole and 300 μg/ml Domperidone   (solution A). 
From the solution A, 1 ml was transferred to volumetric 
flask of 10 ml capacity and volume was made up to the 
mark using mobile phase to give a solution containing 10 
μg/ml Ilaprazole and 30 μg/ml Domperidone. This 
solution was used for the estimation of Ilaprazole and 
Domperidone. 
 
TABLE 7: Analysis of market formulation 
Drug Label claim 
(mg) 
Conc. taken 
(μg/ml) 
Average Peak 
Area* 
Conc. found from 
Mixture as per label claim (mg) 
Assay* ± SD 
(%) 
Ilaprazole 10 10 1107.373 9.79 97.92 ± 
0.56 
Domperidone 30 30 1430.931 29.59 98.65 ± 
0.04 
*n=3 
 CONCLUSION 
The proposed RP-HPLC method was used for the 
simultaneous estimation of Ilaprazole and Domperidone 
was found to be sensitive, accurate, precise, simple, and 
rapid. Hence the present RP-HPLC method may be used 
for routine analysis of the raw materials as well as 
combined dosage formulations containing Ilaprazole and 
Domperidone. 
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